• 6,000,000 Americans have heart failure
• This costs our nation >$30bn/year
• >50% of patients have a form of heart failure, heart failure with preserved ejection fraction (HFpEF), for which we have few treatment options
• Heart failure is a leading cause of hospitalizations and death every year
• Currently there is only 1 FDA approved therapy to treat HFpEF
Nature Medicine, volume 27, pages1477–1482 (2021)
Tried and true method to extend half-life, and reduce CNS penetration of suitable small molecules
Does not reduce bioavailability after oral administration
Same technology used for Movantik®
in vivo
in vivo
Patentability and FTO assessment performed by Global Patent Group, LLC
FTO cleared and path identified for broad composition of matter IP protection
Patent application filed by WashU in July 2018, key claims upheld by international searching authority
Treatment of HFpEF (see PIROUETTE trial)
Prevention of post MI heart failure
Treatment of Muscular dystrophy associated cardiomyopathy (Orphan indication, see Pirfenidone in mdx mice)
Prevention of Post-op Afib (see Pirfenidone studies in dogs)
Prevention/treatment of Immunotherapy associated myocarditis e.g., COVID-related)
Treatment of Idiopathic pulmonary fibrosis (current application of Pirfenidone)
Etc.
Douglas Mann, MD
Founder, Chief Scientific Advisor
Luigi Adamo, MD, PhD
Founder, CEO
Jennifer Riggs, PhD
Head of Medicinal Chemistry
Bradley Keller, PhD
VP Preclinical Development
Jennifer Baltz, PhD
Chief Operating Officer